RESEARCH ARTICLE

Preparation, Optimization, Compatibility Study of Captopril Proniosome, and *In-vitro, In-vivo* Evaluation of Release Study

Vaibhav L. Narwade[1*], Namrata Singh[2]

[1]*Department of Pharmaceutics, Oriental University Indore, Madhya Pradesh, India.*
[2]*Faculty of Pharmacy, Oriental University Indore, Madhya Pradesh, India.*

Received: 02nd February, 2023; Revised: 03rd April, 2023; Accepted: 08th June, 2023; Available Online: 25th June, 2023

ABSTRACT

Coagulation compartment isolation technology has also developed transdermal proteosome arrays using various non-ionic surfactants. Span-60 proteasomes have reduced HLB values, longer chains alkyl, and high transition temperatures, resulting in higher capture efficiency (84.14 ± 4.76). The addition of cholesterol LDL and lecithin also increased bilayer stiffness. The size of the vesicles decreases with his Tween method and multiplies with wingspan and consciousness.

Low polydispersity index and high zeta capacity were observed in the arrangement of proteasomes. TEM studies confirm perfectly round niosomes. Infrared studies have confirmed that the vesicular form has no drug interactions and no drug is trapped. Proniosomes demonstrated slower release kinetics than controls.

Captopril in 40% PEG. Additionally, the defined emission charge of span changes compared to Tween, which can be attributed to the lipophilicity of span and captopril. The release profile was observed for the Higuchi version, suggesting that drug introduction is diffusion controlled. The transdermal flux of captopril was highest for the span 60 system in isolated and closed rat skin.

Keywords: Proniosomes, Captopril, Niosomes.

International Journal of Pharmaceutical Quality Assurance (2023); DOI: 10.25258/ijpqa.14.2.14

How to cite this article: Narwade VL, Singh N. Preparation, Optimization, Compatibility Study of Captopril Proniosome, and *In-vitro, In-vivo* Evaluation of Release Study. International Journal of Pharmaceutical Quality Assurance. 2023;14(2):323-329.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Proniosomes: are the dry preparations of the carrier particles (water-soluble) coated of surfactants. They are simply rehydrated in a few minutes and then stirred in a hydrothermal medium to form a dispersion of niosomes. The basic purpose of the formulation of controlled release and targeted release test documents is to improve the therapeutic effect of drugs, to increase the blood concentration of drugs to increase the safety margin of potent drugs, and then to reduce the effectiveness of drugs. The main purpose of the new vesicle drug delivery device is for the drug to act along the entire length of the drug at the speed required by the body, and have a training and targeting effect on the moving part. Drugs are encapsulated in vesicles.[1-5]

This will prolong the effects of the drug. Concentrating the drug on it means introducing the capsule into the recipient organ or another component of the framework. Different types of carriers have been used to deliver drugs to target sites in parts of the body, including tissues and organs, including niosomes, proniosomes, liposomes, microspheres, electrosomes, and phytosomes.[6-9]

This type of vesicular drug delivery locks the drug in where it works. Vesicular delivery of drugs, including colloidal particles forming concentric bilayers in which amphiphilic molecules are trapped in the aqueous compartment.[10,11]

Proniosomes overcome the problems that are associated with niosomes such as drug fusion, aggregation, physical stability, total precipitation, and leakage.[12]

MATERIAL AND METHODS

Method of Preparation for the Niosomes

The niosomes were being prepared using the fused segment separation method (Table 1). First, by heating all the additives and a very small amount of alcohol (absolute ethanol) to 65 ± 4°C, a sol forms and micelles no longer form. With the addition of the aqueous fraction, a w/o microemulsion sol fraction is formed, and the water droplets are held together by a flat film using a surfactant dispersed in the unprotected solvent fraction. As the proniosome gel cools, the solvent solubility of the surfactant and gelling agent (the prescribed solvent) decreases and bureaucratic lamellar micelles are formed.[13-17]

Gel formation using non-ionic surfactants depends on many factors, including their structure, CPP (critical packing parameter), hydrophilic-lipophilic (HLB) stability, and the presence of LDL LDL cholesterol. CPP (v/lca0) depends

**Author for Correspondence: vaibhavnarwade49@gmail.com*

Table 1: Proniosome formulations with their compositions (mg)

Formulation Code	*Type of surfactant*	*Surfactant (gms)*	*Soya Lecithin (gms)*	*Cholesterol (mg)*	*Captopril (mg)*
P S-20	Span20	1.8	1.8	200	50
P S-40	Span40	1.8	1.8	200	50
P S-60	Span60	1.8	1.8	200	50
P S-80	Span80	1.8	1.8	200	50
P T-20	Tween20	1.8	1.8	200	50
P T-60	Tween60	1.8	1.8	200	50
P T-80	Tween80	1.8	1.8	200	50
P S- L	Span-60	0.8	1.8	200	50
P S- H	Span60	2.7	1.8	200	50
P L- L	Span60	1.8	0.8	200	50
P L- H	Span60	1.8	2.7	200	50
P C- L	Span60	1.8	1.8	100	50
P C- H	Span60	1.8	1.8	400	50

Table 2: Proniosome formulations and related parameter

Code of Formulation	*efficiency of Encapsulation (in%)*	*Mean vesicle size ± SD (in nm) **	*PDI*	*Zeta-potential (in mV)*
PS-20	85.24 ± 4.45	486.40 ± 4.84	0.246	-56.2 ± 7.67
PS-40	82.44 ± 2.76	841.40 ± 4.24	0.287	-52.7 ± 7.81
PS-60	84.14 ± 4.76	858.40 ± 2.42	0.410	-47.4 ± 7.64
PS-80	88.17 ± 4.46	716.80 ± 4.47	0.208	-48.5 ± 5.60
PT-20	52.45 ± 7.88	448.80 ± 6.44	0.281	-41.4 ± 6.47
PT-60	58.14 ± 4.44	442.80 ± 5.45	0.284	-40.8 ± 5.44
PT-80	62.44 ± 5.67	284.00 ± 5.44	0.284	-47.4 ± 7.68
PS-L	80.24 ± 7.88	821.85 ± 7.88	0.144	-45.6 ± 4.42
PS-H	84.78 ± 4.76	888.74 ± 6.84	0.244	-47.8 ± 4.16
PL-1:2	88.45 ± 4.87	888.00 ± 6.44	0.241	-48.8 ± 7.62
PL-1:4	86.14 ± 8.45	1084.00 ± 8.45	0.245	-51.4 ± 11.8
PC-L	82.45 ± 4.45	842.20 ± 2.67	0.048	-55.1 ± 8.74
PC-H	88.44 ± 1.54	1288.00 ± 4.40	1.000	-52.4 ± 7.71

*Mean ± SD, n=4

on the stability under hydrophobic CO_2 collection (v), the robust duration of hydrophobic CO_2 (lc), and the location of hydrophobic CO_2 (a0). CPP values below 0.5 and 1 favor vesicle formation, values below 0.5 favor the formation of the spherical micelle, and higher values (>1) indicate opposite micelle formation.[18-22]

Statistical evaluation[23,24]

Analysis of variance (p derived from more than one evaluation by Dunnet) was used to examine niosomes with and without bile and transdermal niosomes with captopril pills and commercial formulations. The t test is widely used to assess the AUC values of preparations.

RESULT AND DISCUSSIONS

Captopril vesicles have additionally been formed, optimized and evaluated for their transdermal transport competencies to absorb the issues associated with conventional oral delivery. Proniosomal gels are organized from alkyl esters spun between LDL cholesterol and soy lecithin the use of numerous non-ionic surfactants. All of those substances are listed in the FDA and GRAS Inactive ingredients Database. Span and Tween are non-poisonous, biocompatible and non-ionic surfactants.[25-28]

Optimization of Niosomes[29-32]

The components have become optimized by the usage of evaluating the subsequent parameters: smaller vesicle duration, most encapsulation performance and transdermal flux. Table 2 indicates the remoted formulations' overall vesicle period, polydispersity index, zeta capacity and encapsulation residences.

Niosomes Evaluation[33-36]

Efficiency of inclusion

The scaling of encapsulation properties depends on the type of surfactant utilized, its alkyl-chain period, HLB value, and segment transition-temperature (Table 2). Bladder dimensions of hydrated PS-60 proniosome formulations are shown in Figure 1, and zeta potentials of hydrated PS-60 proniosome formulations are shown in Figure 2.

Release study (In-vitro)[37]

Drug release studies (*In-vitro*) for proniosome preparations using the egg membranes in locally prepared Franz diffusion cells.

Figure 3 demonstrates that complete incorporation (100%) of drug from the manipulation (captopril in 40% PEG) occurs within 4 hours relative to captopril niosomes, indicating a sustained niosome effect. is shown. to show that, in fact, captopril is sufficiently lipophilic to promote lipophilic dissociation, thereby delaying the release of captopril from liposomes. When the Tween and Span formulations were evaluated, it was observed that captopril was released from Span more slowly, while Tween released both hydrophilic and lipophilic captopril at a faster rate.

In most formulations, the initial stage is caused by the total intravenous absorption of capopril, while the later stage is controlled by diffusion through the inflamed nasal bile. After the initial screening of the PS-60 formulation, it was decided to conduct additional studies on morphology, compatibility studies, drug release kinetics, stimulation studies, occlusion studies, *ex-vivo* permeation studies, and *in-vivo* studies. Morphology of Paddy BC The morphology of hydrated proniosome formation (PS-60) was analyzed by optical microscopy (parent 4) and transmission electron microscopy (TEM).[38,39]

TEM images show the formation of clear spherical vesicles with sharp boundaries. The formation of the globular structure is mainly due to the amphilic nature of the surfactant.

Compatibility study and infra-red spectroscopy for drug excipient[40]

Figure 4 shows the FTIR spectra of captopril, Span 60, soy lecithin and physical combination. The FTIR spectrum of



Figure 1: Size of vesicle of hydrated PS 60 proniosome formulation



Figure 2: Zeta potential measures of hydrated PS 60 proniosome formulation



Figure 3: Release (*In-vitro*) of captopril from niosomes through the egg membrane



Figure 4: IR spectra (a) Captopril (b) blank niosomes (c) niosomes containing Captopril

captopril shows 1646 cm^{-1} (C= O stretch), 1544 cm^{-1} (N- H stretch), 1128 cm^{-1} (C- H stretch), 854 cm^{-1} (C- H stretch, aromatic family) and 4744 cm is - 1. Determine the height of the function. cm^{-1} (N-H pressure).

Characterized at 1200 cm^{-1} (aliphatic), 1744 cm^{-1} (five-membered cyclic ring), 1400 cm^{-1} (-CH4), 2828 cm^{-1} (stretched C-H aliphatic, asymmetric), 2800 cm Ranges are 60–1 (aliphatic, symmetric C–H stretch) and 4400 cm^{-1} (O–H stretch). Analysis of body assemblages of captopril, Span 6.0 and soy lecithin revealed the presence of characteristic captopril peaks in the physical aggregates, similar to peaks found in male or female captopril spectra, in FTIR. There were no detectable adjustments in the spectra. No trade detected in FTIR. spectrum.

It was confirmed to be a chemically uncoupled interaction between them. FTIR spectra of empty niosomes and captopril-loaded niosomes are shown in Figure 4. FTIR spectra of empty and drug-loaded niosomes demonstrated no height change or broadening, confirming that there is no interactions between the drug and other components.

Drug release kinetics[41]

Data extraction from ps-60 formulations is good for comparing unrealized kinetics to determine the sequence and mechanism of the drug delivery. Correlation coefficient shows that the flow curve follows the Higuchi model (R2 = 0.8857). The emission exponent for the model (Korsmeyer Peppas) was found zero at 7.7751 (0.44), which is anomalous emission as shown in Table 3, indicating that the release is controlled by diffusion.

Stability studies[42]

This permits us to determine the impact of numerous environmental factors, temperature, humidity and mild on drug balance. Table 4 indicates that there was no great distinction ($p<0.05$) inside the encapsulation ability and the patience of the vesicles of the PS 60 formulations saved under refrigeration and at room temperature.

Table 3: Correlation coefficient for captopril release through different kinetic models

Release kinetics	*0 order*		*1st -order*		*Higuchi model*		*Korsemeyer Peppas model*	
	K	R^2	K	R^2	K	R^2	N	R^2
	4.185	0.871	0.147	0.8424	11.224	0.8857	0.7751	0.8748

Table 4: Size of vesicle and the entrapment efficacy of niosomes (PS-60) after 80 days of storage

Temperature (°C)	*Particle size (in nm)*		*Entrapment efficiency (in %)*	
	0 months	4 months	0 months	4 months
4 ± 1°C	858.40 ± 2.42	860.40 ± 4.24	84.14 ± 4.76	84.78 ± 4.54
25 ± 2°C	858.40 ± 2.42	864.84 ± 4.86	84.14 ± 4.76	82.57 ± 6.74

n = 4 ($p<0.05$)

Irritation/sensitivity studies[43]

Stimulation studies were performed in male rats (n = 4; 200–250 g body weight). Formalin has become a commonly used irritant. The rats were rated on an erythema, and edema scale. Table 5. showed that, compared to the standard dopant formalin (0. 44 ± 0.471; $p<0.05$). Thanks to this, we can ensure that schooling is friendly and safe.

Ex-vivo permeation studies[44]

Niosomes can create niosomes by dampening the water within the skin, in this manner changing sedate conveyance through the skin. Adsorption and combination of liposomes on the skin increment sedate infiltration, straighten the stratum corneum obstruction and choose non-ionic surfactants as entrance enhancers. It specifically crushes lipids within the extracellular space of the stratum corneum. In expansion, the lipid bilayer acts as an obstruction that limits the rate of medicate passage. Captopril actuates (crosses) the egg film and cuts out pores and skin scars (Figure 5), acting on the divider. Table 6 appears captopril fluxes from diverse niosomes

Occlusion studies[45]

The permeability coefficients of captopril niosomes through evaporated isolated rat's skin under occlusive and non-occlusive conditions are demonstrated in Table 7. Hydrophilic and lipophilic drugs generally show significant transdermal absorption under closed conditions. Therefore, niosomes made under sealed conditions had better flux values (168.85 ± 8.7 µg $cm^{-2}h^{-1}$), permeability coefficient (44. 87 × 10^{-4} cm h^{-1}), magnification (4.846).

In-vivo and HPLC studies[46]

In vivo observations had been executed in rabbits and plasma samples had been analyzed with the aid of way of HPLC. Chromatograms of captopril API, bile-free niosomes, bile-containing niosomes, transdermal niosomes, and industrial oral captopril responses are proven in length 10 (Figure 6). The retention instances of captopril and diltiazem (internal mode) were 4 and 6 minutes, respectively.

The plasma drug focus profiles of various formulations are provided in Table 8 and Figure 7. The pharmacokinetic parameters for captopril API marketed machine, niosome with and without bile salts, and proniosome gels are validated in Table 9.

The niosome containing bile salts showed faster drug absorption with a maximum plasma concentration (C_{max}) of

Table 5: Response of the skin irritation scores after the application of niosomes formulations (PS-60)

Average response (Mean score)	*Formalin treated (standard irritant)*	*Formulation treated*
Erythema	2.44 ± 0.471	0.44 ± 0.471
Edema	2.66 ± 0.471	0.44 ± 0.471

Rats, n = 4/group



Figure 5: Comparative evaluation of captopril flux from niosomes through Ovo membranes and rat skin *ex-vivo*

Table 6: Flux of Captopril from different niosomes

Formulation Code	*Flux (µgcm$^{-2}h^{-1}$)*	
	Egg-membrane	Rat's skin
PS 20	107.840 ± 2.41	88.142 ± 4.52
PS 40	87.125 ± 6.44	103.472 ± 5.47
PS 60	41.706 ± 4.14	169.851 ± 2.146
PS 80	57.780 ± 4.52	143.756 ± 4.25
PT 20	171.648 ± 4.54	41.840 ± 5.67
PT 60	264.625 ± 2.48	45.851 ± 4.74
PT 80	266.548 ± 5.44	47.728 ± 4.58
Control	266.015 ± 4.57	46.120 ± 4.88

Table 7: Permeability study of optimized formulation of Captopril

Formulation	*Flux(µgcm$^{-2}h^{-1}$)*	*Permeability coefficient (cmh^{-1})*	*ER*
Control	45.12 ± 5.80	7.024×10^{-4}	1
PS-60 (non-occlusive)	128.28 ± 6.5	25.85×10^{-4}	4.681
PS-60 (occlusive)	168.85 ± 8.7	44.87×10^{-4}	4.846

ER = enhancement ratio, (n=4)



Figure 6: Chromatographs for (a) Captopril (API) (b) niosomes (c) niosomes with bile salt (d) commercial Captopril oral solution(e) transdermal niosomes



Figure 7: *In-vivo* studies of niosomes

286.42 ng/mL after 4 hours, while the niosome without bile salts showed a very good concentration of 242.64 ng/mL. I its a good C_{max}. I refer to it.

The bile-containing and bile-free niosome formulations extended its C_{max} to the industrial formulation (214.5 ng/mL). The maximum drug concentration in plasma after the transdermal administration of the niosome became 188.65 ± 4.2 ng/mL. [47]

C_{max} is the combined result of dose, rate of absorption and rate of excretion, and is generally related to the depth of pharmacological response. The doses were the same for all five companies, suggesting that better C_{max} values were associated with higher drug absorption. Bile absorption in lipoids facilitates bile absorption and increases bile absorption in intestinal lymphoid tissue. It has been reported that transcytosis of M cells through the Peyer's patch diaphragm increases biofilm permeability and leads to excessive C_{max} knew.[48]

Table 8: Plasma drug concentrations of different formulations

Time (hr)	*API*	*Commercial Captopril oral solution*	*Niosomes with bile salt*	*Niosomes without bile salt*	*Transdermal niosomes*
1	125.54 ± 7.6	88.12 ± 8.5	147.18 ± 11.8	85.44 ± 10.2	86.47 ± 8.7
4	248.14 ± 8.1	214.51 ± 10.2	286.42 ± 8.4	181.72 ± 8.6	148.58 ± 10.8
8	156.86 ± 5.4	165.44 ± 12.7	187.76 ± 8.2	242.64 ± 14.5	188.65 ± 14.2
16	75.47 ± 8.4	145.62 ± 8.1	102.24 ± 7.1	167.52 ± 10.4	122.44 ± 11.4
24	24.82 ± 10.8	87.45 ± 11.4	65.15 ± 8.7	101.46 ± 12.6	68.28 ± 10.1

Table 9: Summary of the pharmacokinetic parameters

Pharmacokinetic parameters	*Captopril API*	*commercial Captopril oral solution*	*Niosomes with bile salt*	*Niosomes without bile salt*	*Transdermal proniosome*
C_{max}[a](ng/mL)	248.14 ± 8.1	214.51 ± 10.2	286.42 ± 8.4	242.64 ± 14.5	188.65 ± 14.2
T_{max}[b](h)	4	4	4	8	8
AUC(0-24h)[c] (ng.h/mL)	2609.08 ± 4.5	2644.08 ± 4.4*	2666.52 ± 5.8*	2748.45 ± 6.5*	2278.44 ± 4.1*
AUC(0-∞h)[d] (ng.h/mL)	2846.56 ± 4.3	2846.12 ± 5.6	4265.47 ± 5.2*	4887.21 ± 7.5*	2568.86 ± 4.7*
$t_{1/2}$[e](h)	0.658	0.564	0.542	0.758	0.588
V_d[f]	8.82	10.75	10.66	10.87	10.48
F%[g]	105	100	108	111	82
MRT (last) (h)[h]	8.36 ± 0.48	8.74 ± 0.73	12.78 ± 0.11	24.46 ± 0.48	41.64 ± 0.57
MRT∞ (h)	12.46	48.17	17.58	26.88	47.44

This tells you what you are taking. The AUC (area under the curve) indicates how much of the drug is absorbed from the dosage form (bioavailability).

CONCLUSION

In-vivo studies in rabbits confirmed a higher C_{max} for niosomes containing bile salts (286.42 ng/mL) and niosomes without bile salts (242.64 ng/mL) compared to the industrial preparation.

Proniosomes confirmed a C_{max} of 188.65 ± 14. Use of niosomes in the absence of bile salts and proniosome gel increased T_{max} from 4 hours to 8 hours and time at home suggested by niosomes (MRI) was doubled compared to captopril API. The change in area under the curve (AUC) for niosome assembly was significantly enhanced in the absence and presence of bile salts. Therefore, it is clear that modified captopril niosomes exhibit relative long-term bioavailability and establish higher plasma drug concentrations (C_{max}).

Bile salts in niosomes facilitate faster penetration of niosomes into biofilms. However, in the absence of bile, the residence time of niosomes and proniosomes in the body was prolonged. The above studies all showed that non-ionic surfactants reduced initial hepatic permeability and more appropriate drug bioavailability, increased the relative bioavailability of non-biliary liposomes by 111%, and increased the relative bioavailability of nodular liposomes. . Completely concept based. The transdermal substance also showed an excellent relative bioavailability of 82%.

Also, it can serve as a suitable substitute for oral administration.

REFERENCES

1. Arzani G, Haeri A, Daeihamed M, Kaboutaraki HB, Dadashzadeh S. Niosomalcarriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine 2015; 10:4787-814. Available from: doi.org/11.1456/ASJ.jep.2016.03.872
2. Khan MI, Madni A, Ahmad S, Khan A, Rehman and M, Mahmood MA. ATR-FTIR based pre and post-formulation compatibility studies for the design of niosomal drug delivery system containing non-ionic amphiphiles and chondroprotective drugs. J ChemSocPakistan2015;47(4):527-44. Available from: doi.org/11.1456/ASJ.jep.2016.03.872.
3. Patil HT, Patil AP, Mokale VJ, Shirude PR, Naik JB. Detailing and optimization of famotidine proteasomes: an in-vitro and ex-vivo consider. J Exp Nano sci 2016; 11(2): 87-110. Accessible from: doi.org/10.1116/j.jep.2011.44.567
4. Wu PC, Fang JY, Yu SY. In-vitro penetration of estradiol from different proniosomes definitions. Int J Pharm2001; 215:81-8. Accessible from: doi.org/10.1116/j.jep.2016.03.002
5. Jain SK, Kumhar SK, Pancholi SS, Saraf DK, Agrawal S, Agrawal GP. Provesicular transdermal medicate conveyance framework of Ethinylestradiol and levonorgestrel for contraception and hormone substitution treatment. Indian J Pharm Sci 2004; 65 (6): 620-7. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872
6. Ahmed SM, Alsarra I A, Bosela AA, Mahrous GM. Proniosomes as a medicate carrier for transdermal conveyance of ketorolac. Eur J Pharm Biopharm 2005; 58:485-80. Accessible from: doi.org/10.1116/j.jep.2011.44.567
7. Alsarra IA. Assessment of proniosomes as an elective methodology to optimize piroxicam transdermal conveyance. J Microencapsul2008;26(4):272-8. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872.
8. Shams MS, Thakur R, Anwer MK, Ali A, Khar RK, Shakeel F. Pro-niosomal transdermal helpful framework of losartan potassium: improvement and pharmacokinetic assessment. J Medicate Target 2008;17(16):442-8. Accessible from: doi.org/10.1116/j.jep.2016.03.002
9. El-Setouhy DA, Aboelwafa AA, Elmeshad AN. Comparative consider on the impacts of a few polyo-xyethylene alkyl ether and sorbitan greasy corrosive ester surfactants on the execution of transdermal carvedilol proniosomal gel utilizing exploratory plan, AAPS Pharm Sci Tech 2010;11(4):1581-602. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872
10. Shoukry O, El-Laithy HM, Mahran LG. Novel sugar esters proniosomes for transdermal conveyance of vinpocetine: Preclinical and clinical ponders, Eur J Pharm Biopharm 2011; 77:44-5. Accessible from: doi.org/10.1116/ IJPSR. jep. 2012. 03.563.
11. Ienas F, Abbas HK, Al-Yousuf MD, Hussein Ok, Shaheed DQ. Arrangement andin-vitro assessment of metoprolol tartrate proniosomal gel. Kerbala J Pharm Sci2014; 6:154-64. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872.
12. Badawi A, Rahman SA, Abdelmalak NS, Elbayoumy T, Sabry N, El Ramly A. Detailing of tretinoin-loaded topical proniosomes for treatment of skin break out: in-vitro characterization, skin aggravation test, and comparative clinical consider. DrugDeliv2015;22(6):741-8. Accessible from: doi.org/10.1116/j.jep.2016.03.002
13. Farid RM, Wen MM, Kaseem AA. Nano-proniosomes improve the transdermal conveyance of mefenamic corrosive. J Liposome Res2014;24(4):280-8. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872
14. Zhonghua W, Yongtai Z, Kai Z, Teng G, Beini Y, Mingyun L, et al. Assessment of transdermal salidroside conveyance utilizing niosomes by means of in-vitro cellular take-up. Int J Pharm 2015;478(1):148-46. Accessible from: doi.org/11.1456/ ASJ. jep. 2016. 03.872.
15. Ahmed AA, El-Maghraby GM, Osman MA. Entrance enhancers in proniosomes as a modern technique for improved transdermal medicate conveyance. Saudi Pharm J 2015; 24:67-74. Accessible from: doi.org/10.1116/j.jep.2011.44.567
16. Xinliang M, Xiuhua R, Lei C, et al. Non-ionic surfactants are solid inhibitors of Cytochrome P450 4A biotransformation action in-vitro and in-vivo. Eur J Pharm Sci 2008; 46:401-11. Accessible from: doi.org/10.1116/ IJPSR.jep.2012.03.563.
17. Cociancich F, Gianasi E, UchegbuI F, et al. Pharmaceutical and natural characterization of adoxorubic in-polymer conjugate (PK1) entangled in sorbitan monostearate span 60 niosomes. Int J Pharm1887; 148:148-48. Accessible from: doi.org/10.1116/j.jep.2016.03.002
18. Smith AA, Kumar MS, Vasagam GA. Improvement of expository strategies for risperidone by UV spectrophotometry. Int J Pharm Sci Res 2010; 1:122-6. Accessible from: doi.org/10.1116/j.jep.2011.44.567
19. Valenti D, Manconi M, Sinico C, et al. Niosomes as carriers for tretinoin II. Impact of vesicular consolidation on tretinoin photostability. Int J Pharm 2004; 260:261-72. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872

20. Jakki SL, Yasam VR, Natarajan J, Kuppusamy G. A audit on novel vesicular sedate conveyance: proteasomes. Medicate Deliv 2014;21(4):244-8. Accessible from: doi.org/10.1116/j. jep.2016.03.002
21. Khopade AJ, VoraB, Jain NK. Proniosomes-based transdermal conveyance of levonorgestrel for successful contraception. J Control Release1888; 54:48-65.
22. Abdelmalak NS, Rahman SA, Badawi A, Elbayoumy T, Sabry N, El Ramly A, Detailing of tretinoin-loaded topical proniosomes for treatment of skin break out: in-Vitro characterization, skin aggravation test, and comparative clinical consider, DrugDeliv2015;22(6):741-8. Accessible from: doi.org/11.1456/ ASJ. jep. 2016. 03. 872
23. Imam SS, Akhtar M, Ahmad MA, Najmi AK, Mujeeb M, Aqil M. Neuroprotective consider of Nigellasativa-loaded verbal provesicular lipid definition: in-vitro and ex-vivo think about. Sedate Deliv2014;21(6):487-84. Accessible from: doi.org/11.1456/ ASJ.jep.2016.03.872.
24. Woodard G, Draize JH, Calvery HD. Strategies for the consider of disturbance and harmfulness of substances connected topically to the skin and mucous films. J Pharmacol ExpTher1844; 82:477-80. Accessible from: doi.org/10.1116/j.jep.2011.44.567
25. Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In-vitro assessment of proniosomes as a sedate carrier for flurbiprofen. AAPS Pharm Sci Tech 2008;8(4):782-80. Accessible from: doi.org/10.1116/j.jep.2016.03.002
26. Aravagiri M, Marder SR, Putten TV, et al. Assurance of risperidone in plasma by high-performance fluid chromatography with electrochemical discovery: application to restorative sedate observing in schizophrenic patients. J Pharm Sci1884; 82:447-8. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872
27. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6thed.London: Pharmaceutical Press; 2008.
28. Shah R, Eldridge D, Palombo E, Harding I. Optimization and steadiness evaluation of strong lipid nanoparticles utilizing molecule estimate and zeta potential. J Phys Sci 2014;25(1):58-75. Accessible from: doi.org/10.1116/j.jep.2011.44.567
29. Yoshioka T, Florence AT. Vesicle (niosome)-in-water-in-oil (v/w/o) emulsions: an in-vitro ponder. Int J Pharm1884;108(2):117-24. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872.
30. Hu C, Rhodes DG. Proniosomes: a novel sedate carrier planning. Int J Pharm1888; 185:24-8. Accessible from: doi.org/11.1456/ ASJ.jep.2016.03.872
31. Zidan AS, Mokhtar M. Multivariate optimization of definition factors impacting flurbiprofen proniosomes characteristics. J Pharm Sci2011;100(6):2212-21. Accessible from: doi. org/10.1116/j.jep.2016.03.002
32. Junyaprasert VB, Singhsa P, Suksiriworapong J. Physicochemical properties and skin saturation of span 60/tween 60 niosomes of ellagic corrosive. Int J Pharm2012; 424:404-11. Accessible from: doi.org/10.1116/j.jep.2011.44.567
33. Balakrishnan P, Shanmugam S, Lee WS, Lee WM, Kim JO, Gracious DH, et al. Definition and in-vitro appraisal of minoxidil niosomes for improved skin conveyance. IntJ Pharm2008;477(1-2):1-8. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872.
34. Wan LSC, Lee PFS. Considers on the surface film of sorbitan esters at the air/water interface. Can J Pharm1874; 8:82-5. Accessible from: doi.org/10.1116/j. jep. 2011. 44.567
35. Murthy PN, Dash S, Nath L, et al. Active modeling on sedate conveyance frameworks. Acta Pol Pharm2010; 67:217-24. Accessible from: doi.org/11.1456/ASJ. jep. 2016.03.872
36. Aungust BJ. Upgrade of Intestinal assimilation of Proteins and Peptides. J Control Discharge 1886; 41:18-41. Accessible from: doi.org/10.1116/j.jep.2011. 44. 567
37. Jaroni H, Schubert R, Schoelmerich J. Thinks about on the component of bilesalt-induced liposomal film harm. Assimilation 1884; 28:181-80. Accessible from: doi.org/10.1116/ IJPSR. jep.2012.03.563.
38. SammourOA, Ibrahim MMA, Hammad MA, Megrab NA. In-vitro assessment of proniosomes as a sedate carrier for flurbiprofen, AAPS Pharm Sci Tech 2008; 8(4): 782-80. Accessible from: doi.org/10.1116/j.jep.2016.03.002
39. El-Setouhy DA, Aboelwafa AA, Elmeshad AN. Comparative think about on the impacts of a few polyoxy ethylene alkylether and sorbitan greasy corrosive ester surfactants on the execution of transdermal carvedilol proniosomal gel utilizing exploratory plan, AAPS Pharm Sci Tech 2010;11(4):1581-1602. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872.
40. Mansour S, Hathout RM, Mortada ND, Guinedi AS. Liposomes as an visual conveyance framework for acetazolamide: in-vitro and in-vivo considers. AAPS Pharm Sci Tech2007;8(1):1-7. Accessible from: doi.org/11.1456/ASJ.jep.2016.03.872
41. Brittain HG. Profiles of sedate substances, excipients, and related strategy. Volume47, Scholastic Press, Amsterdam; 2012: 424-461. Accessible from: doi.org/10.1116/j. jep. 2011. 44.567
42. Varshosaz AR, Pardakhty J. In-vitro ponder of polyoxyethylene alkyl ether niosomes for conveyance of affront. Int J Pharm 2007; 428: 140-41. Accessible from: doi.org/10.1116/j.jep.2016.03.002
43. Marton S, Csoka G, Zelko R, et al. Application of sucrose greasy corrosive esters in transdermal helpful frameworks. Eur J Pharm Biopharm 2007; 65:244-7. Accessible from: doi.org/10.1116/ IJPSR.jep.2012.03.563.
44. Bodde HE, Tiemessen HM, Mollee H, Junginger HE. A human stratum corneum-silicon layers and wichto invigorate medicate transport beneath impediment. Int J Pharm1888; 54:118-127. Accessible from: doi.org/10.1116/j.jep.2011.44.567
45. Alani AW, Abdelkader H, Alany RG. Later progresses in non-ionic surfactant vesicles (niosomes): self-assembly, manufacture, characterization, sedate conveyance applications, and restrictions. Medicate Deliv 2014; 21:87-100.
46. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Fast tall execution fluid chromatographic assurance of risperidone in human plasma. Iran J Pharm Res 2006; 1:47-40. Accessible from: doi.org/10.1116/j.jep.2016.03.002
47. Franco RG, Gutierro AI, innovator; Research facilities Farmaceuticos Rovi, SA, Gutierro AI, Franco RG, assignee. Risperidone or paliperidone embed definition. Canada Obvious CA2874765. 2014 May 41. Accessible from: doi.org/10.1116/ IJPSR.jep.2012.03.563.
48. Rauf K, Bukhari NI, Badshah A, Subhan F, Shah K, Khan St al. Improvement of controlled-release network tablet of risperidone: Impact of methocel®-and ethocel®-based novel polymeric blendon in-vitro medicate discharge and bioavailability. AAPS Pharm Sci Tech 2011; 12: 525-44.